About Jenburkt
Jenburkt is a publicly listed company based in Mumbai (India) founded in 1985 by Harshad Bhuta, Hemendra Bhuta, and Uttam Bhuta. It operates as a manufacturer of pharmaceutical formulations and prescription medications. The company has 779 employees. Its Indian entity Jenburkt Pharmaceuticals Ltd reported revenue of ₹158 Cr. Jenburkt offers products and services including Favivent and Nutraceuticals. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
Jenburkt was founded in 1985 in Mumbai, India, within the pharmaceutical sector. Formulations and prescription medications are produced across areas like pain management, anti-infectives, and consumer products. A WHO-GMP approved facility is utilized for manufacturing, alongside a dedicated RD unit for healthcare innovations. Distribution occurs both domestically and internationally.
- Headquarters Mumbai, India
- Employees 779
- Founders Harshad Bhuta, Hemendra Bhuta, Uttam Bhuta
- Stage Public
- SectorsHealthcare
- Website jenburkt.com
- Social LinkedIn X Facebook Instagram
- Legal Name Jenburkt Pharmaceuticals Ltd
- Annual Revenue₹158 Cr
FY 2025 · +8% YoY
- Net Profit₹32.06 Cr
FY 2025 · 20% margin
- EBITDA₹47.11 Cr
FY 2025 · 30% margin
- Employee Count779
Associated legal entities of Jenburkt
Jenburkt operates through Jenburkt Pharmaceuticals Ltd, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Jenburkt Pharmaceuticals Ltd Listed CIN L24230MH1985PLC036541 | Active | 10 Jun 1985 | Mumbai, Maharashtra | ₹158 Cr | 765 | 8 | View details |
Products & Services of Jenburkt
Jenburkt offers a comprehensive portfolio of products and services, including Favivent and Nutraceuticals.
Favivent is offered as a prescription medication for COVID-19 treatment under accelerated approval, where it is administered under medical supervision for effective outcomes.
Nutraceuticals are provided in various therapeutic areas, where they are designed to support health outcomes through quality formulations accessible worldwide.
Board of directors of Jenburkt Pharmaceuticals Ltd (Jenburkt)
Jenburkt Pharmaceuticals Ltd is the primary company behind Jenburkt. The board of Jenburkt Pharmaceuticals Ltd currently have 6 directors; the longest-serving is Ashish Uttam Bhuta, appointed in 2007. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ashish Uttam Bhuta DIN 00226479 | Managing Director | 02 Jun 2007 | 19 yrs 4 mo | Jenburkt Pharmaceuticals Ltd |
| Dilip Harkishandas Bhuta DIN 03157252 | Whole-time director | 16 Jul 2013 | 13 yrs 2 mo | Jenburkt Pharmaceuticals Ltd |
| Hina Ravindra Mehta DIN 08719453 | Director | 28 Mar 2020 | 6 yrs 6 mo | Jenburkt Pharmaceuticals Ltd |
| Sumit Ajaybhai Thakkar DIN 10157663 | Director | 26 Jul 2023 | 3 yrs 2 mo | Jenburkt Pharmaceuticals Ltd |
| Pankaj Arun Dantwala DIN 02158836 | Director | 28 May 2024 | 2 yrs 4 mo | Jenburkt Pharmaceuticals Ltd |
| Krishnan Subharaman DIN 01518995 | Director | 28 May 2024 | 2 yrs 4 mo | Jenburkt Pharmaceuticals Ltd |
People of Jenburkt
4 people are tracked at Jenburkt (4 in leadership); the tracked headcount is 779.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
Hemendra Bhuta | Co-Founder | Leadership |
| Co-Founder & MD | Leadership | |
| Managing Director | Leadership |
Complete people profiles for Jenburkt
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Jenburkt
Jenburkt is a publicly listed company on the BSE with ticker symbol JENBURPH in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Nov 2000
- Listed onBSE: 524731
- Listed entityJenburkt Pharmaceuticals Ltd
- Exchange sectorHealth technology
- ISININE354A01013
- Share price₹1,152.80 (-0.87% on the day) · 2026-05-11
- Market capitalisation₹513 Cr
- Price to earnings14.6
- EPS (diluted, trailing year)₹78.70
- Dividend yield1.55%
- Volume (last session)1,863
- Analyst consensusNo rating
Financials of Jenburkt
Figures of Jenburkt Pharmaceuticals Ltd, the primary company behind Jenburkt, for FY 2025. Revenue was ₹158 Cr (+8% year on year). Net profit was ₹32.06 Cr (20% margin). EBITDA was ₹47.11 Cr (30% margin). Revenue has grown at a compounded annual rate of +7% over three years and +5% over five years.
- ₹158 CrRevenue · FY 2025 · +8% YoY
- ₹32.06 CrNet profit · 20% margin
- ₹47.11 CrEBITDA · 30% margin
- ₹4.41 CrPaid-up capital
- 765Employees (provident fund records)
- +7%Revenue CAGR, 3 years
- +5%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | ₹169 Cr | ₹34.7 Cr | ₹46.3 Cr |
| 2024 | ₹152 Cr | ₹32.1 Cr | ₹41.2 Cr |
| 2023 | ₹142 Cr | ₹26.0 Cr | ₹33.7 Cr |
| 2022 | ₹137 Cr | ₹24.6 Cr | ₹30.9 Cr |
| 2021 | ₹124 Cr | ₹22.3 Cr | ₹27.3 Cr |
Balance sheet, profit and loss, cash flow and ratios of Jenburkt Pharmaceuticals Ltd are on its company page.
Detailed financial statements for Jenburkt
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Jenburkt
The website of Jenburkt (jenburkt.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▲ 39.5% vs previous month
Websites whose visitors overlap most with Jenburkt. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| calyxindia.com | 100% | 1K | #7,901,342 | View details | |
etopmeds.com | etopmeds.com | 94% | – | #11,697,640 | – |
| entodpharma.com | 94% | 3.9K | #4,955,160 | View details | |
| mangalamdrugs.com | 91% | 9.9K | #1,747,627 | View details | |
| naxparlab.com | 86% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Jenburkt
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
10 companies that operate in the same segment as Jenburkt (Traditional Health & Nutrition), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | – | USD 3.02 B | 8,300 | |
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | – | USD 5.1 B | 13,500 | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | Petah Tikva, Central District, Israel | USD 500 M | USD 18.74 B | 51,792 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | – | USD 508.93 M | 5,180 | |
Pharmaceutical products are developed and marketed globally. | 2009 | Montville, New Jersey, United States | USD 155.92 M | – | – | |
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | – | USD 6.21 B | 25,870 | |
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations | 1991 | Delhi, Delhi, India | USD 367.2 M | USD 1.52 B | 21,320 | |
Generics, biosimilars, APIs, and vaccines are manufactured by Wockhardt. | 1967 | Mumbai, Maharashtra, India | – | USD 353.53 M | 3,410 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jenburkt
Complete news archive for Jenburkt
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jenburkt
Jenburkt was founded in 1985.
Jenburkt is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Jenburkt has 779 employees.
The primary company behind Jenburkt, Jenburkt Pharmaceuticals Ltd, reported revenue of ₹158 Cr for FY 2025, up 8% year on year.
Jenburkt was founded in 1985 in Mumbai, India, within the pharmaceutical sector. Formulations and prescription medications are produced across areas like pain management, anti-infectives, and consumer products. A WHO-GMP approved facility is utilized for manufacturing, alongside a dedicated RD unit for healthcare innovations. Distribution occurs both domestically and internationally.
Jenburkt offers Favivent and Nutraceuticals.
Yes, Jenburkt is publicly traded on BSE under the ticker symbol JENBURPH.
Jenburkt operates through Jenburkt Pharmaceuticals Ltd.
The legal entities of Jenburkt currently have 7 directors, including Hina Ravindra Mehta, Dilip Harkishandas Bhuta, Ashish Uttam Bhuta and others.